anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide the cleansing cosmetic containing as a base material a solubilized composition comprising an anionic surfactant, a specific lipophilic nonionic surfactant, an oil component and water, not requiring double face- washing after used, and excellent 111 its touch, etc. CONSTITUTION:This cleansing cosmetic contains as a base agent a solubilized composition comprising an anionic surfactant, a lipophilic nonionic surfactant having an HLB value of &lt;=10, an oil component (e.g. liquid paraffin, olive oil, squalane), and water. The lipophilic nonionic surfactant is preferably an N- acylglutamic acid ester of the formula (R1 is 7-21C alkyl or alkenyl; R2, R3 are sterol, 1-22C alkyl, 2-22C alkenyl; (m),(n) are 0-30). The anionic surfactant is preferably N-acylglutamic acid salt, N-acylmethyltaurine salt, etc. The cleansing cosmetic does not require double face washing after used, and is excellent in cleansing force, touch and storage stability in skin-wetted states.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide fusion of Fc domains with biologically active peptides and pharmaceutical agents and compositions using biologically active peptides.  &lt;P&gt;SOLUTION: Pharmacologically active compounds are prepared by a process comprising: (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, RNA-peptide screening, or chemical-peptide screening.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present application is directed to an anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment or prevention of shock in a patient, wherein said patient is characterized by having a level of dipeptidyl peptidase 3 (DPP3) in a sample of bodily fluid below a threshold, which is &lt; 40 ng/ml or in the range between 22 and 40 ng/ml and said anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold binds to the N-terminal part (amino acid 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 14). The present application further relates to a method for the prediction of an increase of dipeptidyl peptidase 3 (DPP3) in a critically ill patient. In particular, the method comprises providing a sample from said patient, determining a level of Dipeptidyl peptidase 3 (DPP3) in said sample, comparing said level to a pre-determined threshold, wherein the level of DPP3 in said sample is indicative of an increase of DPP3 if said level of DPP3 is above a pre-determined threshold level, which is in the range between 22 and 40 ng/ml. Furthermore, the present application also relates to a method for the prevention of a DPP3 increase in a critical ill patient, wherein a DPP3 inhibitor is administered to the patient if the level of DPP3 is above a threshold between 40 ng/ml and 22 ng/ml and said DPP3 inhibitor is an anti-DPP3-antibody and/ or and anti-DPP3-antibody fragment and/ or anti-DPP3 scaffold. Moreover, the present application also relates to a DPP3 inhibitor for use in the prevention of a DPP3 increase in a critical ill patient.
Particles of a (primary) oil-in-hydrophilic liquid emulsion containing a thickening agent in the hydrophilic liquid phase are encapsulated by forming a secondary emulsion comprising the said primary emulsion dispersed in a coacervating medium comprising an aqueous dispersion of at least two coacervating polymers, at least one of which is a hydrophilic colloid and at least one of which is a linear macromolecular synthetic polymer and causing the polymers to coacervate and thus coat the dispersed primary emulsion particles by altering the pH or by dilution with water.  Suitable thickening agents are: acacia, tragacanth, methyl- and carboxymethyl-cellulose, magnesium aluminium silicate, polyglycols, glycerin and syrups.  As hydrophilic colloids there are mentioned gelable and nongelable hydrophilic colloids e.g. gelatine, agar, albumen, alginates, deacetylated chitin, acacia, starch and fibrinogen.  Suitable polymers are those whose structure comprises both lipophilic and hydrophilic units, e.g. styrene-maleic acid amide and methyl-vinyl ether-maleic acid copolymers, polymethacrylic acid, carbohydrate acetate phthalates and (preferably) hydrolysed styrene-maleic anhydride copolymers and modifications thereof, in particular those of general formula [-R-R1-]n, wherein R represents lipophilic polymer units of which more than 70% are styrene residues and R1 represents hydrophilic units of which more than 50% are maleic acid residues. Solubilizing agents may be added to increase the concentration of polymer, e.g. solvents and polysaccharides, e.g. alginates, pectins, methyl- and carboxymethyl-cellulose and Irish moss derivatives. Either or both phases of the primary emulsion may contain dissolved or suspended &#34;active&#34; ingredients which render the product of the invention useful as sustained release fertilizers, plant growth regulants, bactericides, and pesticides, as food additives, cosmetic ingredients and medicines.  Specific examples include: (a) mineral oil-in-caffeine aqueous suspension in gelatine and styrene-maleic acid copolymer, and (b) corn oil-in-aqueous rotenone suspension in fibrinogen and cellulose acetate phthalate.  Specification 751,600 is referred to.
PROBLEM TO BE SOLVED: To obtain a medicinal composition which increases sustainability of an active ingredient in blood, possesses excellent movalility to tissues and is effective for improvement of a variety of nervous symptoms by combination of a vitamin B1 derivative or its salt and a specific compound. SOLUTION: As this composition, a vitamin B1 derivative or its salt and idebenone are simultaneously used. By this combination, conversion of the vitamin B1 derivative or its salt absorbed from digestive tract into thiamine with SH compounds in blood is suppressed and movement to target tissues such as nervous tissues is increasable. The vitamin derivative (salt) and idebenone are formulated in amounts of 1-500 pts.wt. and 1-500 pts.wt., respectively. As the salt of vitamin B1 derivative, fursultiamine hydrochloride is particularly preferable. This medicinal composition is particularly effective for nervous symptoms caused by Alzheimer&#39;s disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a skin care preparation suitable for producing good stimulation in an esthetic treatment.  &lt;P&gt;SOLUTION: The skin care preparation comprises (1) an N-acylglutamic acid diester and (2) a polyglycerin having a polymerization degree of 2-5. Preferably the skin care preparation comprises further an alkylene oxide methylsiloxane copolymer. Preferably the skin care preparation contains 10-30 mass% of glycerin and is an oil-in-water-in-oil type dosage form. Preferably, the skin care preparation is a skin protection agent before pack treatment in aesthetics.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
This invention describes novel immunogenic complexes designed to trigger a host immune response against cancer cells by co-opting the immune system&#39;s natural ability to eliminate pathogen-infected host cells. The immunogenic complexes, referred to as microbial mimetics, have unique physical and biochemical properties, designed to simulate a pathogenic infection of similar sized bacteria and viruses, permitting tumor-associated and tumor-specific peptide antigens to be presented to immune cells as microbial constituents. The MM are well-suited to mimic a systemic infection with microbe sized particles comprised largely of tumor antigens. Under this framework, tumor cells may be eliminated in the ensuing immune response. The MM exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The MM constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aerosol agent containing percutaneous absorption medicine restrained from the occurrence of dripping at an applied part.  &lt;P&gt;SOLUTION: A button 1 is pressed down to apply force to a valve through a stem 5 to thereby open the valve, and the content sealed in a container 6 is jetted in mist, paste, or the like from a nozzle hole 2. In this case, protrusions 3 provided on both sides of the nozzle hole act as baffles, and the content is jetted in a jet pattern spreading flat in a longitudinal direction. The aerosol agent can be widely used for medication means by percutaneous absorption such as external administration or inhalation administration and is applicable for prevention and treatment of various diseases, relaxation of various symptoms, etc. according to the kind or the like of percutaneous absorption medicine in use.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel antitumor composition effective via the oral route obtained through extraction/concentration by an efficient method without spoiling antitumor activity which inexpensive edible basidiomycete has, and to provide food containing the composition.  &lt;P&gt;SOLUTION: The antitumor composition is obtained through eliminating insoluble substance and fractions each having a molecular weight of ≤100,000 from hydrothermal extract obtained by subjecting Lyophyllum ulmarium fruit body to hydrothermal treatment. Another version of the composition is obtained by making anion-exchange resin adsorb the composition followed by liquating out the composition. A method for producing the antitumor composition is provided. Food or a beverage containing the composition is provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To provide an ultraviolet ray intercepting agent having extremely high safety to the skin and capable of protecting the skin from ultraviolet rays, by using kojic acid as an effective component. CONSTITUTION:An ultraviolet ray intercepting agent obtained by dissolving kojic acid, e.g. in water or ethanol, or dispersing the acid in a proper oily substance in the presence of a surface active agent. The ultraviolet ray intercepting agent thus prepared may be added to cosmetics, ointment, etc. The amount of the agent to be added is 0.1-5wt%. Kojic acid can be prepared by the liquid culturing of kojic acid-producing fungi such as those belonging to Aspergillus genus, Penicillium genus, etc. Fermented foods such as &#39;&#39;miso&#39;&#39;, soy sauce, &#39;&#39;sake&#39;&#39;, etc. contains kojic acid as a tasting component. Therefore, the agent has extremely low toxicity, and is free from skin irritation and allergic activity.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bill medical entry device for enabling even a person who has used a bill medical entry sheet being a paper medium to easily enter medical treatment fee in a bill medical entry sheet displayed on a picture.  &lt;P&gt;SOLUTION: This bill medical entry device acquires bill medical display data from a hard disk, and displays the image of a bill medical entry sheet on a display. When deciding that a certain region on the bill medical entry sheet displayed on the display has been selected by a mouse or the like, the bill medical entry device performs the input processing of a medical treatment fee for displaying a medical treatment fee which can be input to the region. When deciding that the input to the selected region has been ended, the bill medical entry device displays the input medical treatment fee on the bill medical entry sheet displayed on the display. Thus, it is possible to easily enter the medical treatment fee on the bill medical entry sheet displayed on the picture.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain an ideal sticking agent for external use which is free from contact with air by forming the tacky adhesive agent compsn. consisting of an A-B-A type block copolymer, softener, water absorptive polymer, and alicyclic petroleum resin. CONSTITUTION:The A-B-A type block copolymer refers to a block copolymer of a monovinyl substd. arom. compd. A and conjugate, diolefin copolymer B and the compounding ratio thereof is specified to 10-30 pts.wt. in the tacky adhesive agent compsn. The water absorptive polymer refers to the polymer which gelatinizes and swells by absorbing water of &gt;=10 times its own weight and is prepd. by properly mixing 1 or &gt;=2 kinds of the water absorptive polymers introduced with a light crosslinking bond with, for example, a water soluble polymer. The ratio of said polymer to be compounded is 1-10 pts.wt. in the tacky adhesive agent compsn. The alicyclic petroleum resin refers to a petroleum resin having cyclic skeleton and the ratio of said resin to be compounded is 10-50 pts.wt. Higher fatty acid, liquefied rubber, mineral oil, etc., are used for the softener and the ratio of the softener to be compounded is 10-50 pts.wt. The base is selected from stretchable or non-stretchable bases consisting of, for example, polyethylene, etc.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of pharmaceutical and food industry, in particular to production of vitamin-mineral complexes (VMC) and food additives, used for prevention and treatment of vitamin-mineral deficiency. Simultaneously, taken into account are all antagonistic and synergic interactions between active VMC components, arising in production, storage and application of medication. Delivery of micronutrients by time and place of their digestion is realised within one preparative form, which is made in form of tablet or capsule, containing several independent elements - pellets. Pellets have their time of dissolution, depending on acidity of surrounding medium. During movement of ready form along GIT time of beginning of substances release from one pellet follows time of end of substances release from other pellet in such a way that simultaneously in solution there were no active substances that have antagonistic interaction. ^ EFFECT: invention is aimed at increase of VMC efficiency and improvement of user&#39;s comfort during its application. ^ 23 cl, 10 ex, 2 tbl
The present invention provides an isolated GABAB receptor protein comprising at least one GABABR1 a subunit and at least one GABABR2a subunit, characterized in that said GABAB receptor has one high affinity agonist binding site and one low affinity agonist binding site. In particular the isolated recombinant GABAB receptor protein expressed by the hGABABR1a/GABABR2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-K1 h-GABA-b R1a/R2 clone on August 22,2003 with the accession number LMBP 6046CB. It is thus an object of the present invention to provide the hGABABR1a/GABABR2 CHO cell line deposited at the Belgian Coordinated Collections of Microorganisms (BCCM) as CHO-KI h-GABA-b R1a/R2 clone on August 22, 2003 with the accession number LMBP 6046CB. 20 The invention also provides the use of the aforementioned cell line in a method to identify GABAB receptor agonists using a functional or a binding assay. In particular in a radioligand-binding assay comprising the use of radiolabeled agonists such as for example &lt;3&gt;H-GABA or &lt;3&gt;H-baclofen. In a particular embodiment the present invention provides the use of the aforementioned GABAB receptor in a method to identify a high affinity GABAB receptor agonist using a functional or a binding assay. In particular in a radioligand-binding assay comprising the use of radiolabeled agonists such as for example &lt;3&gt;H-GABA or &lt;3&gt;H-baclofen. Alternatively, the aforementioned binding assays are performed on cellular extracts, in particular cellular membrane preparations of the aforementioned cells.
PROBLEM TO BE SOLVED: To obtain a flutamide composition excellent in eluting ability and absorbability in vivo and capable of reducing adverse effects and a dose required for clinical effects in a therapy of prostatic cancer. SOLUTION: This flutamide composition contains flutamide and a nonionic surfactant as essential ingredients, or a lower polyhydric alcohol ester of a fatty acid can be further added as the essential ingredient. The nonionic surfactant preferably dissolves 100-150mg flutamide at 20 deg.C and polyoxyethylene-cured castor oil is cited as an example. The lower polyhydric alcohol ester of a fatty acid dissolves at least &gt;=20mg flutamide/g ester and a middle chain fatty acid triglyceride is cited as an example. To 1 pt.wt. flutamide, 0.5-10 pts.wt. nonionic surfactant and 0.3-15 pts.wt. lower polyhydric alcohol ester of a fatty acid can be added. The dose is, e.g. 40-80mg flutamide capsule which can be administered once or twice a day.
PURPOSE:To improve the activity of interferon or impart the activity thereto, by treating the interferon with a protein denaturaing agent, diluting the treated interferon with a buffer solution containing a mineral acid salt, adsorbing the diluted interferon on an inorganic adsorbent, and eluting the adsorbed interferon. CONSTITUTION:Interferon is treated with a protein denaturing agent in &gt;=4mol concentration, e.g. urea or guanidine, and then diluted with a buffer solution with a mineral acid salt to give &lt;=1mol concentration of the above-mentioned protein denaturing agent. The resultant diluted solution is then adsorbed on an inorganic adsorbent, e.g. silica based adsorbent, and eluted with an eluent, e.g. alkaline buffer solution at &gt;=8pH or acidic buffer solution at &lt;=3pH, to give the aimed inteferon having improved activity in the eluate. This method is particularly useful for interferon, produced by cultivating a microorganism obtained by the recombinant DNA technique, and having no activity or improving the activity of inactivated interferon.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and method for detecting the presence of pathogenic prions in various specimens, eg., a sample obtained from a living subject, blood products, and feeds for farm animals, and other humans and animals.  &lt;P&gt;SOLUTION: This peptide reagent interacting preferentially with the PrP&lt;SP&gt;Sc&lt;/SP&gt;type of the prion protein is described. The method for using the reagent for detection, diagnosis, purification, treatment and prevention of the prion and the diseases associated with the prion or an antibody to the reagent is also described. These peptide reagents can be used in wide uses such as a tool for isolating the pathogenic prions or for detecting the presence of the pathogenic prions in the specimens, as a component for a composition for the treatment or prevention and/or for the preparation of a prion specific antibody. For example, the peptide reagent interacting preferentially with the PrP&lt;SP&gt;Sc&lt;/SP&gt;as compared with that of PrP&lt;SP&gt;C&lt;/SP&gt;is useful for the diagnosis of the diseases.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention provides a traditional Chinese medicine composition for treating a malignant tumor. The traditional Chinese medicine composition comprises three compositions. A first composition is prepared from the following TCM bulk drugs: gentrin knotweed, ternate buttercup root, cordate houttuynia, Scutellaria barbata, cockroach, pseudobulb of appendiculate Cremastra, rhizoma paridis, safflower, Fructus Gardeniae, chicken&#39;s gizzard membrane, amber, clerodendroa cyrtophyllum, scorpion and root of large-flowered skullcap. A second composition is prepared from the following TCM bulk drugs: ternate buttercup root, cordate houttuynia, Scutellaria barbata, heydyotis, clerodendroa cyrtophyllum, pseudostellaria root, white ginseng, scorpion, gastrodia tuber, wolfberry, safflower, curcuma tuber and honeysuckle. A third composition is prepared from the following TCM bulk drugs: balloonflower root, bitter orange fruit, dried orange peel, tangerine flavedo, loquat leaf, bitter apricot kernel, gingko, tendril-leaved fritillary bulb, light yellow Sophora toot, curcuma tuber, anemarrhena, honeysuckle, lily, catechu and root of large-flowered skullcap. The traditional Chinese medicine composition is applicable to patients with cancers, can protect the patients from the pain of surgery, radiotherapy and chemotherapy and has the advantages of reduction in treatment courses and cost.
A vehicular control system includes an electronic control unit (ECU) disposed at a vehicle. The system is in wireless communication with a remote server. A health monitoring sensor captures sensor data representative of a health condition of an occupant of the vehicle. The system, based on processing at the ECU of captured sensor data, transmits a first signal to the remote server based on the captured sensor data. Responsive to receiving the first signal, the remote server transmits a second signal to the system including at least one destination suitable to treat the health condition of the occupant. Based on the second signal, the system selects a target destination from the at least one destination and determines a path of travel between the vehicle&#39;s current geographic location and the target destination&#39;s geographic location. The system at least partially controls operation of the vehicle along the path of travel.
A universal electronic transaction card (&#34;UET card&#34;) serves as a number of different cards for banking, identification and the like. The UET card includes storage means (34), inputting and display means (30), processing means (33) and communication means (38). The display is a touch sensitive display which provides a number of menus to select the type of card to use for a transaction. After the choice is made, a graphic image appears on the display which looks like the face of the card, including the account number, user&#39;s name, the name of the credit card company and its logo. Thereafter, the user presents the UET card to the point of sales terminal for a sales transaction. The sales transaction information is transferred and stored in the UET card by the point of sales terminal to eliminate paper receipts and facilitate future storage, verification and analysis.
PURPOSE: To obtain the subject composition containing an antibody obtained from an egg yolk of a hen immunized with dog parbovirus and exhibiting preventive effect extremely effective against a parbovirus infectious disease of a young dog or cat in the period at which vaccine can not effectively be affected. CONSTITUTION: This composition contains an antibody obtained from an egg yolk of a hen immunized with a dog parbovirus. An antigen virus is inoculated to egg-laying hen exceeding 200 day age in an viral amount of 10&lt;3&gt; to 10&lt;8&gt; TCID50 (TCID50 is 50% infected amount in a cultured cell) per hen by subcutaneous injection or intramuscular injection. High antibody value is preferably obtained by carrying out additional immunity after 3 to 4 weeks from the first time immunity. An extracting method by chloroform, etc., or precipitation method, etc., for using polyethylene glycol is generally exemplified as a method for recovering an antibody from egg yolk. Furthermore, symptom of vomition or diarrhea accompanied by parbovirus infectious diseases is preferably improved by simultaneously blending the composition with sugar and electrolyte. Further, vitamins are preferably added thereto.